Steven M Albelda
Overview
Explore the profile of Steven M Albelda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
189
Citations
14872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Davis 4th R, Klampatsa A, Cramer G, Kim M, Miller J, Yuan M, et al.
Cancer Res Commun
. 2023 Sep;
3(9):1810-1822.
PMID: 37700795
Significance: Although mesothelioma is difficult to treat, we have shown that combining surgery with a form of radiation, photodynamic therapy, may help people with mesothelioma live longer. In this study,...
12.
Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, et al.
Nat Commun
. 2023 Aug;
14(1):5110.
PMID: 37607999
The desmoplastic stroma in solid tumors presents a formidable challenge to immunotherapies that rely on endogenous or adoptively transferred T cells, however, the mechanisms are poorly understood. To define mechanisms...
13.
Haas A, Golden R, Litzky L, Engels B, Zhao L, Xu F, et al.
Mol Ther
. 2023 Jun;
31(8):2309-2325.
PMID: 37312454
Multiple clinical studies have treated mesothelin (MSLN)-positive solid tumors by administering MSLN-directed chimeric antigen receptor (CAR) T cells. Although these products are generally safe, efficacy is limited. Therefore, we generated...
14.
Jung I, Noguera-Ortega E, Bartoszek R, Collins S, Williams E, Davis M, et al.
Cell Rep Med
. 2023 May;
4(6):101053.
PMID: 37224816
Chimeric antigen receptor (CAR) T cells demonstrate remarkable success in treating hematological malignancies, but their effectiveness in non-hematopoietic cancers remains limited. This study proposes enhancing CAR T cell function and...
15.
Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, et al.
bioRxiv
. 2023 Apr;
PMID: 37090547
The desmoplastic stroma in solid tumors presents a formidable challenge to immunotherapies that rely on endogenous or adoptively transferred T cells, however, the mechanisms are poorly understood. To define mechanisms...
16.
Gong Y, Shao H, Li Y, Brafford P, Stine Z, Sun J, et al.
Cancer Res Commun
. 2022 Nov;
2(8):842-856.
PMID: 36380966
Adoptive cell transfer (ACT) immunotherapy has remarkable efficacy against some hematological malignancies. However, its efficacy in solid tumors is limited by the adverse tumor microenvironment (TME) conditions, most notably that...
17.
Pietrofesa R, Chatterjee S, Kadariya Y, Testa J, Albelda S, Christofidou-Solomidou M
Int J Mol Sci
. 2022 Sep;
23(17).
PMID: 36077483
Although alveolar macrophages play a critical role in malignant transformation of mesothelial cells following asbestos exposure, inflammatory and oxidative processes continue to occur in the mesothelial cells lining the pleura...
18.
Lee I, Noguera-Ortega E, Xiao Z, Todd L, Scholler J, Song D, et al.
Clin Cancer Res
. 2022 Aug;
28(24):5330-5342.
PMID: 35972732
Purpose: Despite the success of chimeric antigen receptor (CAR) T-cell therapy against hematologic malignancies, successful targeting of solid tumors with CAR T cells has been limited by a lack of...
19.
Rurik J, Tombacz I, Yadegari A, Mendez Fernandez P, Shewale S, Li L, et al.
Science
. 2022 Jan;
375(6576):91-96.
PMID: 34990237
Fibrosis affects millions of people with cardiac disease. We developed a therapeutic approach to generate transient antifibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modified messenger RNA...
20.
Good C, Aznar M, Kuramitsu S, Samareh P, Agarwal S, Donahue G, et al.
Cell
. 2021 Dec;
184(25):6081-6100.e26.
PMID: 34861191
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell exhaustion in the...